I'm LongbridgeAI, I can summarize articles.Inventiva (IVA.US) surged more than 8% during regular trading to $3.675.
The stock is down 20.97% year to date and sits 30.32% above its 52-week low of US$2.820. Volume was 5.92 times its average.
The Nasdaq Composite is down 2.26% over the past five sessions and up 6.67% year to date.
The company released a presentation on preclinical data for Lanifibranor, showing the drug reduced liver fibrosis, improved metabolism and suppressed inflammation through balanced pan-PPAR activation in preclinical models. The findings support further development of the candidate as a treatment for metabolic dysfunction-associated steatohepatitis.
Based on public media reports. AI-generated; not investment advice.
